Onxeo Publishes Shareholder Newsletter
(WorldNews France)

Onxeo Publishes Shareholder Newsletter 20 Jan 2020 17:57 CET Company Name ONXEO ISN FR0010095596 Market Euronext Symbol ONXEO Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (`Onxeo` or `the Company`), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces the publication of its shareholder letter. In this new issue, readers will find out about Onxeo`s perspectives for 2020 and the clinical development plan of AsiDNATM, notably about an upcoming clinical study designed to evaluate the effect of AsiDNATM in combination with...